Member Info for inanaco

Due to air arse Oles ... Gap filling by dentists will not be allowed .. those engaged in Gap filling are doing so illegally

further details contact the NHS Covid Task force

in the SP ...

missed that bit

Bunsie, Crackin can only read numbers .. the technical descriptions presented by a Scancell RNS are challenging for many inc. Crackin , Scancell rarely mention the word Gap .. other than a "Gap" in the market to allow us the be commercial ..

example ... we don't add toxicity to check points .. thus a "Gap" exists as many combo's do ... ie chemo

Gap in context is a useful word ...

not sure many people Top Up or buy just because they see a Gap ..

Crackin predicts a trend ..... mmm smart guy ... Bell Bottoms are back ...... always a 50% of being correct .. UP or Down

do you think you can predict an RNS on the science ... ?

after all that is what this share is about .. not tossing a coin

yes c7 you was also adverse to BMW's ... driven extremely slowly ... like i do ..

https://www.frontiersin.org/articles/10.3389/fimmu.2017.00430/full

pretty well explains it ..

the bit after "AND".... is pretty powerful ..

Conclusions: Modi-1 citrullinated peptide vaccine induces potent CD4-mediated anti-tumor responses in mouse models and a CD4 T cell repertoire is present in ovarian cancer patients to the citrullinated peptides suggesting that Modi-1 could be an effective vaccine for ovarian cancer patients.

I think to divert attention away from the essence of the posts .. is a bit of a shame ...

ATB

this is well worth a read ............... and pretty well explains why getting the "Platform" correct plays IMHO a more important role than any other against Cancer and Virus ....

Critical to almost all functions of the adaptive immune response is the activation and programming of T cells from their naïve/resting state. Although there is much more to be learned, we now have a good basic understanding of the signals and cell types involved in the various stages of the T cell response initiated within the secondary lymphoid organs (SLOs). To provide a comprehensive overview, this review will summarize the T cell response broken down into three major stages: activation, differentiation, and memory formation. We will then assemble these components into a description of the anatomy of an immune response and its relationship to productive immune protection.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4089090/

Scancell developed there own Mouse ...

and even mice have control arms

I am trying to point out that enormous resource that is and has been directed at the Target Antigen and to find it

cancer can evade that by Loss of expression .... of MHC 1 and MHC 2

or indeed have no expression at all .............. A cold cancer

Avidmab does not need MHC 1 or MHC 11 because its locking on to specific sugars so it bypasses one area that cancer uses to evade

"""" recognise glycan-containing glycoproteins and glycolipids on the cell surface of cancer cells."""

Immunobody is bringing in High Avidity T cells that can lock onto poor MHC 1 expression ... and kill the cell.. but a poor vaccine or natural response ( high avidity is deleted in the thymus) induces T cells that are of low affinity, then the cancer can then start losing that antigen thus evading the vaccine or natural response .

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323381/

Moditope on the other hand being a CD4 with TH1 high inflammatory profile .......... forces the cancer to EXPRESS the target antigen via its MHC 11 pathway
will those same CD4 bring in other parts of the immune system to extend its full capability Ie Nk Cells ?

I asked this question to Lindy .. reply "aware of capability" but we have not looked at discovery of any "extras" principally because Moditope was so effective as a stand alone in it self. They probably did not need to look at what else is going on, as maybe they would have to build a different model to find out IMHO

and from the papers presented ... Homocitrulline induces even higher levels of cytokine forcing further expression potentially in cold cancers

you are Correct Nom ......... it is gambling because of "leverage" it amplifies losses or profits

therin lies the problem

the problem you are talking about affects the entire country ..... and how various illness can be accommodated while a pandemic is still evident

its like i said to TF 2 months ago ........ People will not wear masks correctly and struggle with the notion of social distancing

impossible to control without draconian rules and a Police Force that Polices by Fear ....

Good News thou ......... Scancell is not an Airline

The rise of T helper TCRs
Whereas cellular anti-tumour immune responses have typically been attributed to CD8 T cells, CD4 T cells play a critical role in tumour elimination and in the priming and maintenance of CD8 T-cell responses (recently reviewed in [33], Fig. 2). Moreover, CD4 T cells activate innate cells such as macrophages and NK cells to contribute to anti-tumour responses and can also have direct cytotoxic effect against tumour cells expressing MHC class II [34,35,36]. The use of MHC class II-restricted CD4 T cells for adoptive immunotherapy has been limited due to (1) a lack of well-characterized shared tumour antigens presented by MHC class II, (2) the majority of tumour cells being class II negative and therefore not directly presenting antigen to CD4 T cells, and (3) the lack of tools to evaluate CD4 TCR efficacy. However, the use of CD4 T cells in ACT should also circumvent one of the common tumour escape mechanisms, which is the loss of MHC class I to prevent recognition by the immune system [37]. All clinical studies of TCR therapy published to date, except one [38], have used MHC class I restricted TCRs (recently reviewed in [39]). MHC class II-restricted CD4+?T cells are able to induce more robust and broader anti-tumor immune responses which could improve outcomes in cancer immunotherapy.

Moditope forces the cells to Present MHC 11 .........................it only needs to inflame .. make hot ... create inflammation

so while the "others " ie Big Pharma are scratching heads .. what is the Target antigen ? and with the majority of cancer NOT displaying MHC 11

Scancell hits the sweet spot ..............

coming soon to a patient near you ... Modi1

https://link.springer.com/article/10.1007/s00262-019-02468-9

https://ashpublications.org/blood/article/109/12/5346/23092/CD4-cells-can-be-more-efficient-at-tumor-rejection

Scancell have not directly looked at this area in the Pre-clinical but Scancell is aware of what a CD4 can do hence inclusion in the SCIB1 and SCIB2 vaccine ...

we can picture a communication triangle in which tumor-specific CD4 cells activate NK cells via a DC bridge and/or NK cells help to sustain the CD4 response through the activation of DCs. A variation of this scenario comes from a previous report suggesting that CD4 T cells might also partner with tumor-infiltrating macrophages.17,22 At first glance, such a duo might seem less likely than that of the CD4/NK cell partnership, given that tumor-infiltrating macrophages have been shown to support tumor growth by promoting angiogenesis and tissue remodeling and repair.59,60 However, CD4 cells are effective educators of other cells: they can license DCs to activate CD8 killers,43 they can educate DCs to perpetuate oral tolerance,61 and they can induce B cells to switch to a different class of antibody. It is only a small step to suppose that tumor-specific CD4 cells could recognize tumor-infiltrating macrophages, via cross-presented tumor antigens, and alter their phenotype from “tumor-nurturing” to “tumor-rejecting.” Overall, it seems that CD4 T cells may partner with many different types of host cells to clear the tumor, something that CD8 cells may be less able to do.

This is why I call them the General ..

coming to a Patient near you .... Modi1

at least the air bridge is open with BioNtech ...

well said post rec.

actually Ivy i am not concerned at all by a low SP ... seems that there is always somebody to buy them ... which cancels out your negativity ...
the market has two sides ...
as a constant buyer of Scancell the lower the better ...

at the end of the day .... if the trials come good, all is well .. and i do not think for one second the sp will be 6p

so rather than selling before we engage on the trial journey and the results from the collaboration's at this very low SP like you ......

I am a buyer .............

and every one that sells is selling to a party with the opposite view

and its that what makes the market ..

You are only One side ..

Tick Tock

I appreciate Wimbledon is cancelled ... but lets not play the game here

ATB